<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03016650</url>
  </required_header>
  <id_info>
    <org_study_id>muharrem-1</org_study_id>
    <nct_id>NCT03016650</nct_id>
  </id_info>
  <brief_title>Opioid-sparing Effect of Intravenous Ibuprofen</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muharrem Ucar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to evaluate tramadol-sparing effect of intravenous (IV) ibuprofen in
      patients undergoing percutaneous nephrolithotomy (PCNL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty patients who will undergoing PCNL are randomized to intravenous paracetamol (n=40) and
      intravenous ibuprofen (n=40) groups. Patients will receive 100 mL of physiologic saline with
      1 g IV paracetamol or 800 mg IV ibuprofen 30 minutes before the end of the operation and
      postoperatively 6, 12 and 18 hours after PCNL in the paracetamol and ibuprofen groups,
      respectively. Patients in both groups will receive intravenous tramadol with patient
      controlled analgesia device (PCA).

      The visual analog scale (VAS) will used to evaluate pain intensity scores in the
      postoperative period.

      Total tramadol consumption, mean VAS score in the 1, 8 and 24 hours, demographic variables,
      operative variables, and side effects will record.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine Consumption</measure>
    <time_frame>postoperatively 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>postoperatively 30 minute, 2, 4, 6,12 and 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Analgesia</condition>
  <condition>Percutaneous Nephrolithotomy</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Perfalgan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL</description>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>Intrafen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study include 80 patients of American Society of Anesthesiologists (ASA) physical
             status I-II aged between 18-70 years who scheduled for percutaneous nephrolithotomy
             operation.

        Exclusion Criteria:

          -  chronic pain,

          -  psychiatric disease,

          -  renal dysfunction,

          -  allergy to nonsteroidal anti-inflammatory drugs,

          -  history of drug addiction,

          -  pregnancy,

          -  inability to use a patient controlled analgesia (PCA) device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muharrem Ucar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ä°nonu University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muharrem Ucar, Asst.Prof.</last_name>
    <phone>+90 422 341 06 60</phone>
    <phone_ext>3136</phone_ext>
    <email>umuharrem@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehmet ALi ERDOGAN, Ass.Prof.</last_name>
    <phone>+90 422 341 06 60</phone>
    <phone_ext>6419</phone_ext>
    <email>drmalierdogan@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Maghsoudi R, Tabatabai M, Radfar MH, Movasagi G, Etemadian M, Shati M, Amjadi M. Opioid-sparing effect of intravenous paracetamol after percutaneous nephrolithotomy: a double-blind randomized controlled trial. J Endourol. 2014 Jan;28(1):23-7. doi: 10.1089/end.2013.0267. Epub 2013 Oct 17.</citation>
    <PMID>23952097</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Muharrem Ucar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Ibuprofen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

